Literature DB >> 28748165

Triple antithrombotic therapy in patients undergoing percutaneous coronary intervention: balancing between ischemia and bleeding.

Konstantinos C Koskinas1, Lorenz Räber1.   

Abstract

Entities:  

Year:  2017        PMID： 28748165      PMCID： PMC5509926          DOI： 10.21037/cdt.2017.04.02

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN： 2223-3652


× No keyword cloud information.
  10 in total

1.  Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.

Authors:  Lorenz Räber; Michael Magro; Giulio G Stefanini; Bindu Kalesan; Ron T van Domburg; Yoshinobu Onuma; Peter Wenaweser; Joost Daemen; Bernhard Meier; Peter Jüni; Patrick W Serruys; Stephan Windecker
Journal:  Circulation       Date:  2012-02-01       Impact factor: 29.690

2.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.

Authors:  Katrin A Fiedler; Michael Maeng; Julinda Mehilli; Stefanie Schulz-Schüpke; Robert A Byrne; Dirk Sibbing; Petra Hoppmann; Simon Schneider; Massimiliano Fusaro; Ilka Ott; Steen D Kristensen; Tareq Ibrahim; Steffen Massberg; Heribert Schunkert; Karl-Ludwig Laugwitz; Adnan Kastrati; Nikolaus Sarafoff
Journal:  J Am Coll Cardiol       Date:  2015-04-28       Impact factor: 24.094

4.  Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention.

Authors:  Rahman Shah; Glenda Delgado; Shannon W Finks
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

5.  Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).

Authors:  Gregory Y H Lip; Stephan Windecker; Kurt Huber; Paulus Kirchhof; Francisco Marin; Jurriën M Ten Berg; Karl Georg Haeusler; Giuseppe Boriani; Davide Capodanno; Martine Gilard; Uwe Zeymer; Deirdre Lane; Robert F Storey; Hector Bueno; Jean-Philippe Collet; Laurent Fauchier; Sigrun Halvorsen; Maddalena Lettino; Joao Morais; Christian Mueller; Tatjana S Potpara; Lars Hvilsted Rasmussen; Andrea Rubboli; Juan Tamargo; Marco Valgimigli; Jose L Zamorano
Journal:  Eur Heart J       Date:  2014-08-25       Impact factor: 29.983

6.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

7.  Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Konstantinos C Koskinas; Lorenz Räber; Thomas Zanchin; Thomas Pilgrim; Stefan Stortecky; Lukas Hunziker; Stefan Blöchlinger; Michael Billinger; Fabienne Gartwyl; Christina Moro; Aris Moschovitis; Peter Jüni; Dik Heg; Stephan Windecker
Journal:  JACC Cardiovasc Interv       Date:  2016-07-25       Impact factor: 11.195

8.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

9.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Authors:  C Michael Gibson; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W Verheugt; Peter Wildgoose; Mary Birmingham; Juliana Ianus; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric D Peterson; Keith A Fox
Journal:  N Engl J Med       Date:  2016-11-14       Impact factor: 91.245

10.  Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.

Authors:  C Michael Gibson; Duane S Pinto; Gerald Chi; Douglas Arbetter; Megan Yee; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W A Verheugt; Peter Wildgoose; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Purva Jain; Gregory Y H Lip; Marc Cohen; Eric D Peterson; Keith A A Fox
Journal:  Circulation       Date:  2016-11-14       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.